Two Sigma Advisers LP purchased a new position in shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 88,000 shares of the biotechnology company’s stock, valued at approximately $779,000.

Several other large investors have also recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth about $3,111,000. venBio Select Advisor LLC grew its holdings in shares of Iovance Biotherapeutics by 18.5% during the fourth quarter. venBio Select Advisor LLC now owns 10,261,039 shares of the biotechnology company’s stock worth $90,810,000 after purchasing an additional 1,598,319 shares during the last quarter. Broadfin Capital LLC grew its holdings in shares of Iovance Biotherapeutics by 21.6% during the fourth quarter. Broadfin Capital LLC now owns 5,951,153 shares of the biotechnology company’s stock worth $52,668,000 after purchasing an additional 1,056,792 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth about $538,000. Finally, Prosight Management LP grew its holdings in shares of Iovance Biotherapeutics by 48.5% during the fourth quarter. Prosight Management LP now owns 1,062,500 shares of the biotechnology company’s stock worth $9,403,000 after purchasing an additional 347,183 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

Several analysts have recently weighed in on the company. Oppenheimer restated a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, March 19th. ValuEngine upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. BidaskClub upgraded Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, Zacks Investment Research upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Friday, January 4th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $22.86.

Shares of IOVA stock opened at $11.28 on Wednesday. Iovance Biotherapeutics Inc has a one year low of $7.26 and a one year high of $18.25.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2019/04/17/two-sigma-advisers-lp-purchases-shares-of-88000-iovance-biotherapeutics-inc-iova.html.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: How a Back-End Load Mutual Fund Works

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics Inc (NASDAQ:IOVA).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.